The Brain Health and Memory Center has established an interdisciplinary care model that has been adopted by neurological institutes nationwide. It has been a leader for research in Alzheimer’s disease and has contributed to studies of the natural history, genetics and behavioral aspects of
Current Clinical Trials
Over the past two decades, our physicians have emerged as leaders in Alzheimer’s disease evaluation and genetic studies. Clinical trials are ongoing to determine the safety and efficacy of pharmaceutical alternatives. Studies change frequently, the following are those we are currently recruiting for:
- Randomized, Controlled Study Evaluating CERE-110 in Subjects with Mild to Moderate Alzheimer’s Disease. The purpose of this study is to evaluate the potential benefits of CERE-110, an experimental drug that is designed to help nerve cells in the brain function better, in the treatment of Alzheimer’s disease. CERE-110 uses a virus to transfer a gene that makes Nerve Growth Factor (NGF), a protein that may make nerve cells in the brain healthier and protect them from dying.
- A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer´s Disease. The purpose of this study is to determine whether IGIV administered at two different doses for nine and 18 months results in a significantly slower rate of decline of dementia symptoms in subjects with mild to moderate Alzheimer´s disease.
- Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer’s Disease on Donepezil (CONCERT). The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer’s disease on Donepezil (Aricept).
- Cataract removal and Alzheimer’s disease. The investigators have designed this study to determine whether or not cataract removal will improve the AD patient’s quality of life, vision and cognition.
- Memantine for the Frontal and Temporal Subtypes of Frontotemporal Dementia. Memantine (Namenda) has been approved for the treatment of Alzheimer’s disease; this study seeks to understand if its use can be applied to Frontotemporal dementia to effectively decrease the rate of behavioral decline in frontotemporal dementia.